Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Clinical Trial 100%
• Adverse Event 50%
• Protein 50%
• Drug Delivery System 50%
• Phosphotransferase 50%
• Protein Tyrosine Kinase 50%
• Non Small Cell Lung Cancer 50%
• Lung Adenocarcinoma 50%
• Sorafenib 50%
• Lenvatinib 50%
• Cabozantinib 50%